Search

ADMA Biologics Inc

Atvērts

SektorsVeselības aprūpe

9.59 0.84

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.33

Max

9.55

Galvenie mērījumi

By Trading Economics

Ienākumi

-7.5M

38M

Pārdošana

9.9M

124M

P/E

Sektora vidējais

13.329

56.659

EPS

0.16

Peļņas marža

30.405

Darbinieki

640

EBITDA

-3.8M

57M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+78.76% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

64M

2.1B

Iepriekšējā atvēršanas cena

8.75

Iepriekšējā slēgšanas cena

9.59

Ziņu noskaņojums

By Acuity

37%

63%

97 / 340 Rangs Healthcare

ADMA Biologics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. aug. 20:07 UTC

ADMA Biologics Inc shares are lower today, continuing a three-day decline. The stock remains significantly below its 20-day moving average amid rising Treasury yields.

2026. g. 27. aug. 19:11 UTC

ADMA Biologics Inc. shares are lower today amid pressure on biotechnology stocks, despite a brief uptick earlier in the session. No specific news was identified.

2026. g. 26. aug. 20:08 UTC

ADMA Biologics Inc. shares are lower amid biotechnology sector weakness, with no specific news identified to explain the decline.

2026. g. 25. aug. 19:26 UTC

ADMA Biologics shares are higher today, supported by declining U.S. Treasury yields that typically enhance equity valuations. No specific company news was identified.

2026. g. 24. aug. 20:06 UTC

ADMA Biologics Inc shares are lower during Monday's session, reversing earlier gains amid broader market influences, including rising oil prices and geopolitical tensions.

2026. g. 21. aug. 23:01 UTC

ADMA Biologics Inc shares declined in after-market trading, continuing a trend of lower finishes over the past three sessions amid broader market volatility.

2026. g. 20. aug. 20:06 UTC

ADMA Biologics Inc shares are lower in Thursday's session, with no specific news identified. Broader market declines may be influencing sentiment amid rising Treasury yields.

2026. g. 19. aug. 20:01 UTC

ADMA Biologics Inc shares are higher Wednesday, continuing a strong upward trend since Tuesday's close, despite no specific news driving the move.

2026. g. 17. aug. 19:36 UTC

Correlated Moves
Social Media
News

ADMA Biologics is trading lower amid an investigation into potential fiduciary breaches by its Board of Directors. Broader market sentiment may also be impacting shares.

2026. g. 13. aug. 20:02 UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

2026. g. 12. aug. 19:46 UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

2026. g. 11. aug. 22:56 UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

2026. g. 7. aug. 19:46 UTC

Correlated Moves
News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

2026. g. 6. aug. 20:02 UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

2026. g. 5. aug. 23:02 UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

2026. g. 4. aug. 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

2026. g. 3. aug. 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

2026. g. 31. jūl. 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

2026. g. 30. jūl. 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

2026. g. 29. jūl. 18:17 UTC

News
Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

2026. g. 28. jūl. 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

2026. g. 27. jūl. 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

2026. g. 24. jūl. 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

2026. g. 22. jūl. 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

2026. g. 21. jūl. 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

2026. g. 20. jūl. 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Salīdzinājums

Cenas izmaiņa

ADMA Biologics Inc Prognoze

Cenas mērķis

By TipRanks

78.76% augšup

Prognoze 12 mēnešiem

Vidējais 17 USD  78.76%

Augstākais 21 USD

Zemākais 12 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ADMA Biologics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

97 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
help-icon Live chat